| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 [P. B., J. L. M., N. R., W. D., J. Y., M. F., K. P., M. J. H.], and Drug Metabolism Department, Abbott Laboratories, Abbott Park, IL 60064 [V. O., A. K.]
A Phase I study of angiogenesis inhibitor TNP-470 was conducted in patients with advanced cancer. TNP-470 (25–235 mg/m2) was administered i.v. over 4 h once a week to patients who had solid tumors refractory to the best available treatment or with a high risk of recurrence and who had normal renal, hepatic, and hematological function and no evidence of coagulopathy. The aims of the study were to determine the maximum tolerated dose, dose-limiting toxicities (DLTs), and the pharmacokinetics of TNP-470 given on a once-weekly schedule. Thirty-six patients, ages 23–75 (median, 54 years), with an Eastern Cooperative Oncology Group performance status of 0–2 were treated. The number of patients at each dose level (mg/m2) were 6 (25), 3 (50), 3 (75), 3 (100), 3 (133), 12 (177), and 6 (235). The principal toxicities of TNP-470 were dizziness, lightheadedness, vertigo, ataxia, decrease in concentration and short-term memory, confusion, anxiety, and depression, which occurred at doses of 133, 177, and 235 mg/m2. Two patients treated at 235 mg/m2 experienced DLT in the form of grade III cerebellar neurotoxicity after 6 weeks of treatment. Overall, these neurological symptoms were dose-related, had an insidious onset, progressively worsened with treatment, and resolved completely within 2 weeks of stopping the drug. One patient with malignant melanoma had stabilization of the previously growing disease for 27 weeks while on the treatment. Two patients, one with adenocarcinoma of the colon and the other with a soft tissue sarcoma, had no clinically detectable disease but were at high risk for recurrence at the initiation of treatment and received 13 months and >3 years of treatment, respectively, with no evidence of disease recurrence. The remaining patients had progression of their disease after 1–6 months of treatment. The mean plasma half-life (t1/2) of TNP-470 and its principal metabolite, AGM-1883, were extremely short (harmonic mean, t1/2 of 2 and 6 min, respectively) with practically no drug detectable in the plasma by 60 min after the end of the infusion. MII, an inactive metabolite, had a considerably longer t1/2 of approximately 2.6 h. Mean peak TNP-470 concentrations were 
400 ng/ml at doses 177 mg/m2. On the basis of this study, the maximum tolerated dose of TNP-470 administered on a weekly schedule was 177 mg/m2 given i.v over 4 h. The principal DLT was neurotoxicity, which appeared to be dose-related and was completely reversible. On the basis of the short plasma t1/2 of TNP-470, exploration of a prolonged i.v. infusion schedule is warranted.
This article has been cited by other articles:
|
|
 |
|
  P. M. Winter, S. D. Caruthers, H. Zhang, T. A. Williams, S. A. Wickline, and G. M. Lanza Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 624 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Winter, A. H. Schmieder, S. D. Caruthers, J. L. Keene, H. Zhang, S. A. Wickline, and G. M. Lanza Minute dosages of {alpha}{nu}{beta}3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits FASEB J, August 1, 2008; 22(8): 2758 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nahari, R. Satchi-Fainaro, M. Chen, I. Mitchell, L. B. Task, Z. Liu, J. Kihneman, A. B. Carroll, L. S. Terada, and F. E. Nwariaku Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Addlagatta and B. W. Matthews Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase Protein Sci., August 1, 2006; 15(8): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chang, J. C. Tou, C. Hong, H.-A. Kim, J. E. Riby, G. L. Firestone, and L. F. Bjeldanes 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice Carcinogenesis, April 1, 2005; 26(4): 771 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Bernier, D. D. Lazarus, E. Clark, B. Doyle, M. T. Labenski, C. D. Thompson, W. F. Westlin, and G. Hannig A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis PNAS, July 20, 2004; 101(29): 10768 - 10773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brakenhielm, R. Cao, B. Gao, B. Angelin, B. Cannon, P. Parini, and Y. Cao Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice Circ. Res., June 25, 2004; 94(12): 1579 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2 Cancer Res., November 15, 2003; 63(22): 7861 - 7869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. M. Bhujwalla, D. Artemov, K. Natarajan, M. Solaiyappan, P. Kollars, and P. E. G. Kristjansen Reduction of Vascular and Permeable Regions in Solid Tumors Detected by Macromolecular Contrast Magnetic Resonance Imaging after Treatment with Antiangiogenic Agent TNP-470 Clin. Cancer Res., January 1, 2003; 9(1): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Herbst, T. L. Madden, H. T. Tran, G. R. Blumenschein Jr, C. A. Meyers, L. F. Seabrooke, F. R. Khuri, V. K. Puduvalli, V. Allgood, H. A. Fritsche Jr, et al. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2002; 20(22): 4440 - 4447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kerbel Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51. [Full Text] [PDF]
|
|
|
|
|
|
S. Shusterman, S. A. Grupp, R. Barr, D. Carpentieri, H. Zhao, and J. M. Maris The Angiogenesis Inhibitor TNP-470 Effectively Inhibits Human Neuroblastoma Xenograft Growth, Especially in the Setting of Subclinical Disease Clin. Cancer Res., April 1, 2001; 7(4): 977 - 984. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Stern, J. Fang, S. Shusterman, G. Pierson, R. Barr, B. Pawel, L. Diller, and S. A. Grupp Angiogenesis Inhibitor TNP-470 during Bone Marrow Transplant: Safety in a Preclinical Model Clin. Cancer Res., April 1, 2001; 7(4): 1026 - 1032. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
